Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (the “Current Report”) is incorporated herein by reference. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 22, 2026, Azitra, Inc.…
Filed Oct 22, 2026Accepted Oct 22, 2026, 4:15 PM EDTCIK 1701478Accession 0001493152-26-048103
We are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties in the skin. As of the date of this prospectus, we have identified among our microbial library over 60 distinct bacterial species that we believe are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.03Item 3.03 - Material Modification to Rights
Item
3.03 Material Modification to Rights of Security Holders.
To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (the “Current
Report”) is incorporated herein by reference.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
October 22, 2026, Azitra, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and
Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate
a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock
(“Common Stock”). At the Company’s annual meeting of stockholders held on June 15, 2026, the Company’s stockholders
approved an amendment to the Company’s certificate of incorporation to effect reverse stock splits of the Common Stock at a ratio
of not less than 1 for 2 and not more than 1 for 30, with the exact ratio for each reverse stock split within such range to be determined
by the Board of Directors in its sole discretion.
The
Reverse Stock Split will become effective on October 26, 2026 at 12:01 a.m., Eastern Time (the “Effective Time”) and the
Common Stock is expected to begin trading on the NYSE American on a Reverse Stock Split-adjusted basis on October 26, 2026 at market
open. As of the Effective Time, every 10 shares of the Company’s issued and outstanding Common Stock will be combined into one
share of Common Stock.
The
par value and other terms of the Common Stock will not be affected by the Reverse Stock Split. The Company’s post-Reverse Stock
Split Common Stock CUSIP number will be 05479L401.
No
fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive
a fractional share of Common Stock will receive a cash payment in lieu thereof at a price equal to (i) the average closing price of the
Common Stock for the five trading days immediately preceding October 26, 2026, multiplied by (ii) the number of shares of Common Stock
outstanding immediately prior to effectiveness of the Reverse Stock Split that were reclassified into such fractional share pursuant
to the Reverse Stock Split.
The
foregoing description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit
3.1 to this Current Report and is incorporated herein by reference.
Forward-Looking
Statements
This
Current Report includes forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “will” and “expected”,
or the negative of such terms, or other comparable terminology, and include statements about the Reverse Stock Split and the impacts,
if any, on the Company’s Common Stock. Forward-looking statements are statements that are not historical facts. Such forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ
materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks,
uncertainties and other factors speak only as of the date of this Current Report, and the Company expressly disclaims any obligation
or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in the Company’s expectations
with regard thereto or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent
otherwise required by applicable law.